Page last updated: 2024-11-04

sulfasalazine and Local Neoplasm Recurrence

sulfasalazine has been researched along with Local Neoplasm Recurrence in 3 studies

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Research Excerpts

ExcerptRelevanceReference
" Secondary outcomes will include the incremental cost per reducing 1 case of relapse; patient reported intolerance to the treatment; adverse events; change of mean disease activity measured by DAS28, clinical disease activity index (CDAI) and simplified disease activity index (SDAI); the proportion of modified Sharp score increase < 0."7.01The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand ( Ji, P; Wu, Y; Yan, X; Yang, L; Zhang, Z; Zhao, J; Zhou, W, 2021)
" Secondary outcomes will include the incremental cost per reducing 1 case of relapse; patient reported intolerance to the treatment; adverse events; change of mean disease activity measured by DAS28, clinical disease activity index (CDAI) and simplified disease activity index (SDAI); the proportion of modified Sharp score increase < 0."3.01The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand ( Ji, P; Wu, Y; Yan, X; Yang, L; Zhang, Z; Zhao, J; Zhou, W, 2021)
"The patient was diagnosed with reactive arthritis associated with BCG intravesical injection therapy, as three typical symptoms were observed (bilateral conjunctivitis, urethritis, polyarthritis)."1.72[A Case of Reactive Arthritis after BCG Intravesical Infusion Therapy Successfully Treated with Salazosulfapyridine]. ( Endo, T; Ishitsuka, R; Kinase, S; Oguni, H; Takahashi, R; Tsutsumi, M; Yanagihashi, R, 2022)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Louis, E1
Paridaens, K1
Al Awadhi, S1
Begun, J1
Cheon, JH1
Dignass, AU1
Magro, F1
Márquez, JR1
Moschen, AR1
Narula, N1
Rydzewska, G1
Freddi, MJ1
Travis, SP1
Takahashi, R1
Kinase, S1
Yanagihashi, R1
Ishitsuka, R1
Endo, T1
Oguni, H1
Tsutsumi, M1
Zhao, J1
Zhou, W1
Wu, Y1
Ji, P1
Yang, L1
Yan, X1
Zhang, Z1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Efficacy, Safety and Cost-effectiveness of Hydroxychloroquine, Sulfasalazine, Methotrexate Triple Therapy in Preventing Relapse Among Patients With Rheumatoid Arthritis Achieving Clinical Remission or Low Disease Activity[NCT02320630]240 participants (Anticipated)Interventional2015-10-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for sulfasalazine and Local Neoplasm Recurrence

ArticleYear
The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand
    BMC medical informatics and decision making, 2021, 03-04, Volume: 21, Issue:1

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Therapy, Combination; Human

2021

Other Studies

2 other studies available for sulfasalazine and Local Neoplasm Recurrence

ArticleYear
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis.
    BMJ open gastroenterology, 2022, Volume: 9, Issue:1

    Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Colitis, Ulcerat

2022
[A Case of Reactive Arthritis after BCG Intravesical Infusion Therapy Successfully Treated with Salazosulfapyridine].
    Hinyokika kiyo. Acta urologica Japonica, 2022, Volume: 68, Issue:5

    Topics: Administration, Intravesical; Aged; Arthritis, Reactive; BCG Vaccine; Carcinoma, Transitional Cell;

2022